TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7509509

Group type: EXPERIMENTAL
Intervention: 750 anti-factor Xa units of Orgaran given subcutaneously twice-daily
Number of subjects: 513

Group type: COMPARATOR
Intervention: 5,000 units standard heparin given twice-daily
Number of subjects: 513
Study: 3207328

Group type: EXPERIMENTAL
Intervention: Size 12 G latex rubber balloon catheter
Number of subjects: 50

Group type: COMPARATOR
Intervention: PVC catheter of similar calibre
Number of subjects: 50
Study: 29607580

Group type: EXPERIMENTAL
Intervention: Antenatal perineal massage (APM)
Number of subjects: 108
Study: 28538393

Group type: EXPERIMENTAL
Intervention: Extraluminal use of Uniblocker (E group, n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intraluminal use of Uniblocker (I group, n=20)
Number of subjects: 40
Study: 26181299

Group type: EXPERIMENTAL
Intervention: Calcium chloride, calcium gluconate, sodium bicarbonate, and regular insulin with dextrose (analyzed as one drug) prepared in various sequences.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Insulin with dextrose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Calcium salts (sodium bicarbonate, calcium chloride, calcium gluconate)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Overall preparation
Number of subjects: 24
Study: 23528523

Group type: EXPERIMENTAL
Intervention: 12-week course of buprenorphine-naloxone with a dose taper to zero in weeks 9-12
Number of subjects: 152

Group type: COMPARATOR
Intervention: 2-week detoxification with buprenorphine-naloxone
Number of subjects: 152
Study: 21575972

Group type: EXPERIMENTAL
Intervention: Intravaginal transobturator monofilament sling with additional 2-point tape fixation
Number of subjects: 463

Group type: COMPARATOR
Intervention: Standard transobturator intravaginal monofilament sling procedure
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Intravaginal transobturator monofilament sling with additional 2-point tape fixation (in patients with intrinsic sphincter deficiency)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Standard transobturator intravaginal monofilament sling procedure (in patients with intrinsic sphincter deficiency)
Number of subjects: 463
Study: 19178514

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Exogenous glucocorticoids
Number of subjects: 123
Study: 16414445

Group type: EXPERIMENTAL
Intervention: Fermentable carbohydrate (FC) supplementation (40 g/d)
Number of subjects: 9
Study: 14504417

Group type: EXPERIMENTAL
Intervention: Scopolamine 0.3 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Scopolamine 0.6 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10856384

Group type: EXPERIMENTAL
Intervention: Patent arteries with <50% stenosis
Number of subjects: 2119

Group type: COMPARATOR
Intervention: Patent arteries with >=50% stenosis
Number of subjects: 2119
Study: 9382012

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study: 8408500

Group type: EXPERIMENTAL
Intervention: Mifepristone (100 mg orally, two doses: 24 and 12 hours before vacuum aspiration)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Mifepristone (100 mg orally, two doses: 48 and 36 hours before vacuum aspiration)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (two doses, timing as per respective groups)
Number of subjects: 38
Study: 3888430

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 30
Study: 29921144

Group type: EXPERIMENTAL
Intervention: PCIT-ED (Parent-Child Interaction Therapy with Emotion Development module)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Waiting list condition (Control)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: PCIT-ED
Number of subjects: 229
Study: 27460780

Group type: EXPERIMENTAL
Intervention: Tangshen Formula (TSF)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 24829362

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (cTnI) concentrations
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Indexed left ventricular (LV) mass and measures of replacement fibrosis (late gadolinium enhancement)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 253
Study: 21988525

Group type: EXPERIMENTAL
Intervention: Multidisciplinary programme (specifics not provided)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Behavioural‐oriented Physiotherapy (PT)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Behavioural Medicine Rehabilitation (BM)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Treatment-as-usual (CG)
Number of subjects: 214
Study: 20195472

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPTp) with sulphadoxine‐pyrimethamine (SP)
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1030
Study: 18479285

Group type: EXPERIMENTAL
Intervention: Tolterodine extended release (ER)
Number of subjects: 863
Study: 15753115

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization
Number of subjects: 813

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 813
Study: 12412687

Group type: EXPERIMENTAL
Intervention: Quantum pressure support ventilator
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sullivan variable positive airway pressure II ST
Number of subjects: 10
Study: 10490440

Group type: EXPERIMENTAL
Intervention: Solar disinfected water
Number of subjects: 349

Group type: COMPARATOR
Intervention: Control (indoor water)
Number of subjects: 349
Study: 7569737

Group type: EXPERIMENTAL
Intervention: Iodixanol 320 mgI ml‐1
Number of subjects: 16

Group type: COMPARATOR
Intervention: Iohexol 350 mgI ml‐1
Number of subjects: 16
Study: 2007848

Group type: EXPERIMENTAL
Intervention: Porcine insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Semisynthetic human insulin
Number of subjects: 0
Study: 6138377

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31274827

Group type: EXPERIMENTAL
Intervention: SAM XT
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet (CAT)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Special Operation Forces Tactical Tourniquet (SOFT‐T)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Previous experience
Number of subjects: 150

Group type: COMPARATOR
Intervention: First-time users
Number of subjects: 150
Study: 28382892

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS), 20 g sachet given from 6 to 18 months
Number of subjects: 728

Group type: COMPARATOR
Intervention: Control group (IFA and MMN combined), no supplementation
Number of subjects: 728
Study: 26529126

Group type: EXPERIMENTAL
Intervention: Broad spectrum antibiotic treatment
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard antibiotic treatment
Number of subjects: 94
Study: 24692325

Group type: EXPERIMENTAL
Intervention: traditional NSAIDs (tNSAIDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: traditional NSAIDs (tNSAIDs) for longer than 365 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: traditional NSAIDs (tNSAIDs) combined with high cardiovascular risk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ibuprofen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: aceclofenac
Number of subjects: 0

Group type: COMPARATOR
Intervention: low-dose aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: paracetamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: metamizole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SYSADOAs
Number of subjects: 0
Study: 22744638

Group type: EXPERIMENTAL
Intervention: Pancreatogastrostomy (PG)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Pancreaticojejunostomy (PJ)
Number of subjects: 116
Study: 19388508

Group type: EXPERIMENTAL
Intervention: Preload/Coload (10 mL/kg before and 10 mL/kg after SAB)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Preload (20 mL/kg crystalloid infusion before SAB)
Number of subjects: 87
Study: 17617272

Group type: EXPERIMENTAL
Intervention: Darunavir-ritonavir 600/100 mg twice daily
Number of subjects: 595

Group type: COMPARATOR
Intervention: Lopinavir-ritonavir 400/100 mg twice daily
Number of subjects: 595
Study: 16371894

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12431044

Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate .025%
Number of subjects: 56

Group type: COMPARATOR
Intervention: Cromolyn sodium 4%
Number of subjects: 56
Study: 10334150

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide inhalation solution 0.02% (qid)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7486611

Group type: EXPERIMENTAL
Intervention: Dextrorphan HCl (Ro 01‐6794/706) administered as a loading dose of 200 mg/hr or greater
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextrorphan HCl (Ro 01‐6794/706) administered as a loading dose below 200 mg/hr
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextrorphan HCl (Ro 01‐6794/706) maintenance dose rate between 50‐90 mg/hr for 24 hours
Number of subjects: 0
Study: 2044394

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (40 mg, 3 times daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (identical to Ginkgo biloba extract)
Number of subjects: 31
Study: 6272566

Group type: EXPERIMENTAL
Intervention: Coarse Canadian Red Spring Wheat bran
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coarse French Soft Wheat bran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fine Canadian Red Spring Wheat bran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fine French Soft Wheat bran
Number of subjects: 0
Study: 31229618

Group type: EXPERIMENTAL
Intervention: Community-friendly Health Recovery Program (CHRP-BB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Time-and-attention matched control condition
Number of subjects: 0
Study: 28670117

Group type: EXPERIMENTAL
Intervention: Dietary beetroot juice (BR) - 2×70 mL twice daily, each containing 300 mg nitrate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dietary beetroot juice (BR)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PL) - 2×70 mL twice daily, nitrate-negligible
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 15
Study: 25315856

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 23866851

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: Venlafaxine-XR
Number of subjects: 2016

Group type: COMPARATOR
Intervention: Brain imaging sub-study
Number of subjects: 2016
Study: 21606530

Group type: EXPERIMENTAL
Intervention: Combined administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: A/H5N1 vaccine
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Solicited local and systemic adverse events
Number of subjects: 401
Study: 20178210

Group type: EXPERIMENTAL
Intervention: Sonic power toothbrush
Number of subjects: 171

Group type: COMPARATOR
Intervention: Rotation/oscillation power toothbrush
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 171
Study: 30232958

Group type: EXPERIMENTAL
Intervention: Single oral dose of salbutamol/ambroxol fixed-dose combination granules
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multiple doses of salbutamol/ambroxol fixed-dose combination granules
Number of subjects: 12
Study: 12940388

Group type: EXPERIMENTAL
Intervention: Multisession, small-group experimental condition encouraging peer outreach
Number of subjects: 250

Group type: COMPARATOR
Intervention: Equal-attention control condition
Number of subjects: 250
Study: 10708006

Group type: EXPERIMENTAL
Intervention: CPRV (n = 114)
Number of subjects: 363

Group type: COMPARATOR
Intervention: PVRV (n = 117)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: CPRV (n = 132)
Number of subjects: 363
Study: 9085961

Group type: EXPERIMENTAL
Intervention: Intrathecal (I.T.) clonidine 1 microg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous (I.V.) clonidine 4 microg/kg
Number of subjects: 20
Study: 8227762

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment for affective disorders
Number of subjects: 0
Study: 3860660

Group type: EXPERIMENTAL
Intervention: Tissue-brushing only
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Denture-brushing only
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study: 29792202

Group type: EXPERIMENTAL
Intervention: Text-message programme in addition to standard care
Number of subjects: 710

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 710
Study: 27592594

Group type: COMPARATOR
Intervention: Daily reminder
Number of subjects: 270

Group type: COMPARATOR
Intervention: Daily lottery-based incentive
Number of subjects: 270

Group type: COMPARATOR
Intervention: Combination of daily lottery-based incentive and reminders
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 270
Study: 25623564

Group type: EXPERIMENTAL
Intervention: Tiotropium bromide (5 µg) via Respimat, once daily for 48 weeks
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study: 23379112

Group type: EXPERIMENTAL
Intervention: Palatoplasty combined tympanostomy tube surgery
Number of subjects: 2

Group type: COMPARATOR
Intervention: Palatoplasty only
Number of subjects: 2
Study: 20635409

Group type: EXPERIMENTAL
Intervention: Monosomy X restricted to the left ventricle in patients with HLHS
Number of subjects: 19

Group type: COMPARATOR
Intervention: Negative control group (chromosomally normal pediatric patients with restrictive or dilated cardiomyopathy)
Number of subjects: 19
Study: 18505669

Group type: COMPARATOR
Intervention: Primary care treatment
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Hospital treatment
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 568
Study: 16150917

Group type: EXPERIMENTAL
Intervention: PYY(3‐36) (0.4 pmol/kg.min) + GLP‐1(7‐36) (0.4 pmol/kg.min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: GLP‐1(7‐36) (0.4 pmol/kg.min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: PYY(3‐36) (0.4 pmol/kg.min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-dose PYY(3‐36) (100 nmol/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-dose GLP‐1(7‐36) (100 nmol/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-dose PYY(3‐36) (1 nmol/kg) + GLP‐1(7‐36) (10 nmol/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Coadministration in ob/ob and db/db mice
Number of subjects: 10
Study: 12543927

Group type: EXPERIMENTAL
Intervention: Cimetidine-induced hypochlorhydria
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal gastric acidity
Number of subjects: 16
Study: 10870749

Group type: EXPERIMENTAL
Intervention: Standard pain scales used in clinical trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard pain scales
Number of subjects: 0
Study: 8639012

Group type: EXPERIMENTAL
Intervention: Diffuse atherosclerosis present in 525 (21%) of participants.
Number of subjects: 2531

Group type: EXPERIMENTAL
Intervention: Factors associated with diffuse atherosclerosis include increased age, being unmarried, being retired, having less than a high school education, increased alcohol use, hypertension, cigarette smoking, and diabetes.
Number of subjects: 2531
Study: 1814742

Group type: EXPERIMENTAL
Intervention: Microencapsulated potassium chloride tablet (MET)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Potassium chloride solution (PS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Potassium chloride wax-matrix tablets (WMT)
Number of subjects: 12
Study: 6235834

Group type: EXPERIMENTAL
Intervention: Spironolactone (50-200 mg daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 30591065

Group type: EXPERIMENTAL
Intervention: Healthy dieting consultations (7 sessions)
Number of subjects: 0
Study: 27733250

Group type: EXPERIMENTAL
Intervention: Saturated fatty acid (SFA) diet for 24 hours
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Saturated fatty acid (SFA) breakfast
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Saturated fatty acid (SFA) diet after an overnight fast
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Saturated fatty acid (SFA) diet after returning to control diet
Number of subjects: 38

Group type: COMPARATOR
Intervention: Carbohydrate (CARB) diet for 24 hours
Number of subjects: 38
Study: 24118040

Group type: COMPARATOR
Intervention: Control (no supplements)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Milk-containing LNS
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Soy-containing LNS
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Corn-soy blend (CSB)
Number of subjects: 840
Study: 22443427

Group type: EXPERIMENTAL
Intervention: Vorapaxar (2.5 mg daily)
Number of subjects: 26449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26449
Study: 20391891

Group type: EXPERIMENTAL
Intervention: High resistance exercise (n = 20)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (n = 23)
Number of subjects: 43
Study: 18030518

Group type: EXPERIMENTAL
Intervention: Pre-neoadjuvant chemotherapy (NACT) with silver wire markers for tumor margins
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Post-NACT wide local excision (WLE) incorporating pre-NACT margins
Number of subjects: 40

Group type: COMPARATOR
Intervention: Post-NACT margins used to guide WLE
Number of subjects: 40
Study: 15915833

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 7
Study: 11988148

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy with latex (active treatment)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study: 10367539

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2/week intravenously diluted in 250 cc of normal saline as 20 minutes infusion for 3 consecutive weeks followed by a 1 week rest period
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2/week
Number of subjects: 24
Study: 8731874

Group type: EXPERIMENTAL
Intervention: Nonoperative treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Operative treatment
Number of subjects: 24
Study: 1856249

Group type: EXPERIMENTAL
Intervention: Ferric maltol (10 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ferric maltol (60 mg elemental iron as tablets)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ferrous sulphate (equivalent dose)
Number of subjects: 21
Study: 7024580

Group type: EXPERIMENTAL
Intervention: sulfamethoxazole-trimethoprim
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: streptomycin
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: sulfisoxazole
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: sulfisoxazole and tetracycline
Number of subjects: 35
Study: 31476782

Group type: COMPARATOR
Intervention: PLAC+SIE
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AHM+SIE
Number of subjects: 12

Group type: COMPARATOR
Intervention: PLAC
Number of subjects: 12
Study: 28864708

Group type: EXPERIMENTAL
Intervention: Carnosine (2 g daily in two divided doses)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 50
Study: 25467171

Group type: EXPERIMENTAL
Intervention: Progressive task-oriented training on a supplementary tilt table (EG2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Only the affected side knee belt of the tilt table was fastened and progressive task-oriented training was performed using the less-affected lower extremity (EG2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Only the affected side knee belt of the tilt table was fastened and one-leg standing training was performed using the less-affected lower extremity (EG1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both knee belts of the tilt table were fastened (CG)
Number of subjects: 30
Study: 23722974

Group type: EXPERIMENTAL
Intervention: HRC monitoring
Number of subjects: 97
Study: 21426620

Group type: EXPERIMENTAL
Intervention: Experimental group (children read stories enriched with emotional lexicon and participated in conversational language games)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (children did not take part in any special linguistic activities after story readings)
Number of subjects: 100
Study: 19784813

Group type: EXPERIMENTAL
Intervention: Therapeutic angiogenesis (gene and cell therapy)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Gene therapy
Number of subjects: 543
Study: 17762338

Group type: COMPARATOR
Intervention: Referral patterns for advanced lung cancer
Number of subjects: 672

Group type: COMPARATOR
Intervention: Knowledge about chemotherapy benefits in advanced cancer
Number of subjects: 672

Group type: COMPARATOR
Intervention: Referral for further therapy
Number of subjects: 672
Study: 15165921

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11813739

Group type: EXPERIMENTAL
Intervention: Verbal advice plus written prescription (green prescription)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Verbal advice only
Number of subjects: 49
Study: 10676820

Group type: EXPERIMENTAL
Intervention: lesopitron 4‐80 mg/d
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: lorazepam 2‐4 mg/d
Number of subjects: 161

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 161